Rice Hall James & Associates LLC Boosts Stake in Icon Plc $ICLR

Rice Hall James & Associates LLC increased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 151.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 30,146 shares of the medical research company’s stock after acquiring an additional 18,175 shares during the period. Rice Hall James & Associates LLC’s holdings in Icon were worth $3,336,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ICLR. Harris Associates L P acquired a new position in Icon in the 2nd quarter worth about $238,256,000. Capital World Investors grew its holdings in Icon by 555.2% in the fourth quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock valued at $272,688,000 after purchasing an additional 1,268,095 shares during the period. Wellington Management Group LLP increased its position in shares of Icon by 26.6% in the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after buying an additional 975,268 shares in the last quarter. Lyrical Asset Management LP purchased a new stake in shares of Icon in the fourth quarter valued at approximately $176,382,000. Finally, Norges Bank acquired a new position in shares of Icon during the 4th quarter worth approximately $160,073,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Barclays increased their target price on Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research report on Thursday, June 25th. DA Davidson set a $164.00 price target on shares of Icon in a report on Monday, June 1st. BMO Capital Markets upped their price objective on shares of Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Royal Bank Of Canada raised shares of Icon from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $126.00 to $185.00 in a report on Thursday, June 25th. Finally, Leerink Partners set a $145.00 target price on shares of Icon in a research report on Thursday, May 28th. Seven investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $168.73.

Icon Stock Performance

Shares of ICLR opened at $165.76 on Monday. Icon Plc has a 52-week low of $66.57 and a 52-week high of $203.91. The stock has a market cap of $12.69 billion, a PE ratio of 29.49, a price-to-earnings-growth ratio of 8.14 and a beta of 1.22. The firm’s fifty day moving average is $151.11 and its two-hundred day moving average is $136.00. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.